Cipemastat

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cipemastat

CAS No. : 190648-49-8

MCE 国际站：Cipemastat

产品活性：Cipemastat 是一种有效的、人胶原酶 (collagenase) 1，2，3的抑制剂，其 K_i 值分别为 3.0，4.4，3.4 nM。

研究领域：Metabolic Enzyme/Protease

作用靶点：MMP

In Vitro: Cipemastat (Ro 32-3555) is a potent, competitive inhibitor of human matrix metalloproteinases. Cipemastat is selective for collagenase 1, 2 and 3 relative to related matrix metalloproteinases. Cipemastat is also a potent inhibitor of rat collagenase (IC₅₀=44.7±3.4 nM (n=4)). In vitro cartilage degradation ± inhibited IL-1a induced cartilage degradation in vitro in a concentration-dependent manner with an IC₅₀=60 nM. The inhibition is not mediated by a cytotoxic action on explant chondrocytes. Cipemastat, at all concentrations tested, fail to modify glucose utilization when compared to explants cultured in the presence of IL-La alone.

In Vivo: The amount of hydroxyproline in non-implanted cartilage is 119.3±4.2 nM/mg and this decreases in cartilages implanted in vehicle-dosed animals to 53.6±7.1 nM/mg over a fourteen day period. Animals administered Cipemastat orally at doses of 2.5, 5, 10 and 25 mg/kg show statistically increased levels of implanted cartilage hydroxypro-line. Fourteen days after the second challenge injection of P. acnes, the area of cartilage most consistently affected by pannus is the lateral femoral condyle, which is the area analysed. In non-arthritic animals the mean cartilage area is 0.17±0.02 mm² (n=5). In arthritic animals there is a significant decrease to a mean area of 0.086±0.01 mm² (n=10). The group of animals dosed with Cipemastat (50 mg/kg, p.o.) show a significantly greater area of cartilage with a mean value of 0.126±0.012 mm² (n=9). The pannus area in vehicle-dosed animals is 0.099±0.017 mm² and in Cipemastat dosed animals 0.102±0.019 mm². Adjuvant arthritis injection of adjuvant induced two phases of swelling of the injected paw in vehicle-dosed rats. The primary swelling phase occurred between days 0 to 5 and induced an increase in paw volume of 1.9±0.1 mL; the secondary phase occurrs between day 9 to 14 and there was an increase in paw swelling of 0.98±0.08 mL. The group of animals dosed with dexamethasone (0.1 mg/kg) shows a significant reduction in both primary (0.2±0.03 mL) and secondary inflammation (0.07±0.08 mL) paw swelling as well as total inhibition of the lesion score.

相关产品：Bioactive Compound Library Plus  |  Doxycycline hyclate  |  T-5224  |  Ilomastat  |  Chloramphenicol  |  Astragaloside IV  |  Edaravone  |  Isoginkgetin  |  Cordycepin  |  Marimastat  |  GI254023X  |  Stigmasterol  |  Salvianolic acid A  |  o-Phenanthroline  |  Arctigenin  |  Actinonin  |  SB-3CT  |  Meloxicam  |  Batimastat  |  MMP-9-IN-1  |  Chondroitin sulfate  |  GW280264X  |  TAPI-1  |  Aderbasib  |  Tranexamic acid  |  (-)-Epigallocatechin  |  Incyclinide  |  TAPI-2  |  Indinavir sulfate  |  ARP-100

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds